LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 3372

Search options

  1. Article ; Online: The impact of specific cytokine directed treatment on severe COVID-19.

    Reuken, P A / Rüthrich, M M / Hochhaus, A / Hammersen, J / Bauer, M / La Rosée, P / La Rosée, F / Stallmach, A

    Leukemia

    2021  Volume 35, Issue 12, Page(s) 3613–3615

    MeSH term(s) Antiviral Agents/therapeutic use ; COVID-19/diagnosis ; COVID-19/drug therapy ; COVID-19/metabolism ; COVID-19/virology ; Cytokines/metabolism ; Disease Management ; Humans ; Molecular Targeted Therapy ; SARS-CoV-2
    Chemical Substances Antiviral Agents ; Cytokines
    Language English
    Publishing date 2021-09-07
    Publishing country England
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 807030-1
    ISSN 1476-5551 ; 0887-6924
    ISSN (online) 1476-5551
    ISSN 0887-6924
    DOI 10.1038/s41375-021-01411-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2295: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial.

    Hammersen, J / Birndt, S / Döhner, K / Reuken, P / Stallmach, A / Sauerbrey, P / La Rosée, F / Pfirrmann, M / Fabisch, C / Weiss, M / Träger, K / Bremer, H / Russo, S / Illerhaus, G / Drömann, D / Schneider, S / La Rosée, P / Hochhaus, A

    Leukemia

    2023  Volume 37, Issue 9, Page(s) 1879–1886

    Abstract: Dysregulated hyperinflammatory response is key in the pathogenesis in patients with severe COVID-19 leading to acute respiratory distress syndrome and multiorgan failure. Whilst immunosuppression has been proven to be effective, potential biological ... ...

    Abstract Dysregulated hyperinflammatory response is key in the pathogenesis in patients with severe COVID-19 leading to acute respiratory distress syndrome and multiorgan failure. Whilst immunosuppression has been proven to be effective, potential biological targets and optimal timing of treatment are still conflicting. We sought to evaluate efficacy and safety of the Janus Kinase 1/2 inhibitor ruxolitinib, employing the previously developed COVID-19 Inflammation Score (CIS) in a prospective multicenter open label phase II trial (NCT04338958). Primary objective was reversal of hyperinflammation (CIS reduction of ≥25% at day 7 in ≥20% of patients). In 184 patients with a CIS of ≥10 (median 12) ruxolitinib was commenced at an initial dose of 10 mg twice daily and applied over a median of 14 days (range, 2-31). On day 7, median CIS declined to 6 (range, 1-13); 71% of patients (CI 64-77%) achieved a ≥25% CIS reduction accompanied by a reduction of markers of inflammation. Median cumulative dose was 272.5 mg/d. Treatment was well tolerated without any grade 3-5 adverse events related to ruxolitinib. Forty-four patients (23.9%) died, all without reported association to study drug. In conclusion, ruxolitinib proved to be safe and effective in a cohort of COVID-19 patients with defined hyperinflammation.
    MeSH term(s) Humans ; COVID-19 ; Prospective Studies ; Nitriles ; Janus Kinase Inhibitors/adverse effects ; Inflammation/drug therapy ; Treatment Outcome ; Janus Kinase 1
    Chemical Substances ruxolitinib (82S8X8XX8H) ; Nitriles ; Janus Kinase Inhibitors ; JAK1 protein, human (EC 2.7.10.2) ; Janus Kinase 1 (EC 2.7.10.2)
    Language English
    Publishing date 2023-07-28
    Publishing country England
    Document type Multicenter Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 807030-1
    ISSN 1476-5551 ; 0887-6924
    ISSN (online) 1476-5551
    ISSN 0887-6924
    DOI 10.1038/s41375-023-01979-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2295: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Addendum to the German Consensus Recommendations on Ponatinib in the Treatment of Chronic Myeloid Leukemia.

    Saussele, Susanne / La Rosée, Paul / Kiani, Alexander / Haverkamp, Wilhelm / Jentsch-Ullrich, Kathleen / Stegelmann, Frank / Rieger, Christina / Waller, Cornelius F / Franke, Georg-Nikolaus / Junghanss, Christian / Kirchmair, Rudolf / Theurl, Markus / le Coutre, Philipp

    Acta haematologica

    2023  , Page(s) 1–8

    Abstract: Background: Based on the new data from the primary analysis of the OPTIC (Optimizing Ponatinib Treatment in CP-CML) trial on dose optimization of ponatinib in patients with chronic phase (CP)-CML, the German consensus paper on ponatinib published in ... ...

    Abstract Background: Based on the new data from the primary analysis of the OPTIC (Optimizing Ponatinib Treatment in CP-CML) trial on dose optimization of ponatinib in patients with chronic phase (CP)-CML, the German consensus paper on ponatinib published in 2020 (Saussele S et al., Acta Haematol. 2020) has been updated in this addendum.
    Summary: Focus is on the update of efficacy and safety of ponatinib, reflecting the new data set, as well as the update of the benefit-risk assessment and recommendations for ponatinib starting dose in CP-CML - provided that the decision to use ponatinib has already been made. Furthermore, based on OPTIC and additional empirical data, the expert panel collaborated to develop a decision tree for ponatinib dosing, specifically for intolerant and resistant patients. The recommendations on cardiovascular management have also been updated based on the most recent 2021 guidelines of the European Society of Cardiology (ESC) on cardiovascular disease prevention in clinical practice.
    Key messages: The OPTIC data confirm the high efficacy of ponatinib in patients with CP-CML and provide the basis for individualized dose adjustment during the course of treatment.
    Language English
    Publishing date 2023-10-17
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 80008-9
    ISSN 1421-9662 ; 0001-5792
    ISSN (online) 1421-9662
    ISSN 0001-5792
    DOI 10.1159/000533666
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.145: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Erratum zu: Interdisziplinäres COVID-Board bei SARS-CoV-2-getriggerter Hyperferritinämischer Inflammation.

    La Rosée, P / Bremer, H-C / La Rosée, F / Mohm, P / Hochhaus, A / Gehrke, I / Kumle, B / Benzing, A / Russo, S

    Medizinische Klinik, Intensivmedizin und Notfallmedizin

    2020  Volume 116, Issue 2, Page(s) 145

    Title translation Erratum to: Interdisciplinary COVID board for patients with triggered hyperferritinemic Inflammation.
    Language German
    Publishing date 2020-10-25
    Publishing country Germany
    Document type Published Erratum
    ZDB-ID 2636018-4
    ISSN 2193-6226 ; 1435-1420 ; 0723-5003 ; 2193-6218 ; 0175-3851
    ISSN (online) 2193-6226 ; 1435-1420
    ISSN 0723-5003 ; 2193-6218 ; 0175-3851
    DOI 10.1007/s00063-020-00763-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.120: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: The JAK1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

    La Rosee, F. / Bremer, H. C. / Hochhaus, A. / Birndt, S. / Fellhauer, M. / Henkes, M. / Russo, S. G. / La Rosee, P.

    Oncology Research and Treatment

    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #881955
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies.

    La Rosée, Felicitas / La Rosée, Paul

    Acta haematologica

    2020  Volume 144, Issue 3, Page(s) 246–249

    MeSH term(s) COVID-19 ; Hematologic Neoplasms/drug therapy ; Humans ; Pyrazoles/adverse effects ; SARS-CoV-2
    Chemical Substances Pyrazoles ; ruxolitinib (82S8X8XX8H)
    Keywords covid19
    Language English
    Publishing date 2020-08-20
    Publishing country Switzerland
    Document type Editorial ; Comment
    ZDB-ID 80008-9
    ISSN 1421-9662 ; 0001-5792
    ISSN (online) 1421-9662
    ISSN 0001-5792
    DOI 10.1159/000510770
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.145: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Interdisziplinäres COVID-Board bei SARS-CoV-2-getriggerter hyperferritinämischer Inflammation.

    La Rosée, P / Bremer, H-C / La Rosée, F / Mohm, P / Hochhaus, A / Gehrke, I / Kumle, B / Benzing, A / Russo, S

    Medizinische Klinik, Intensivmedizin und Notfallmedizin

    2020  Volume 116, Issue 2, Page(s) 138–145

    Abstract: Background: Patients with severe COVID-19 develop hyperferritinemic inflammation, a rare sepsis-like immune dysregulation syndrome.: Methods: Stratified treatment decisions in a cross-location telemedical interdisciplinary case conference were ... ...

    Title translation Interdisciplinary COVID board for patients with SARS-CoV-2-triggered hyperferritinemic Inflammation.
    Abstract Background: Patients with severe COVID-19 develop hyperferritinemic inflammation, a rare sepsis-like immune dysregulation syndrome.
    Methods: Stratified treatment decisions in a cross-location telemedical interdisciplinary case conference were assessed in this retrospective cohort study. A standardized treatment algorithm including continuous positive airway pressure and noninvasive ventilation was implemented. A locally developed COVID inflammation score (CIS) defined patients at risk for severe disease. Patients with life-threatening inflammation were offered off-label treatment with the immune modulator ruxolitinib.
    Results: Between 4 March 2020 and 26 June 2020 COVID-19 patients (n = 196) were treated. Median patient age (70 years) and comorbidity were high in interstudy comparison. Mortality in all patients was 17.3%. However, advance care planning statements and physician directives limited treatment intensity in 50% of the deceased patients. CIS monitoring of ruxolitinib-treated high-risk patients (n = 20) on days 5, 7, and15 resulted in suppression of inflammation by 42% (15-70), 54% (15-77) and 60% (15-80). Here, mortality was 20% (4/20). Adjusted for patients with a maximum care directive including ICU, total mortality was 8.7% (17/196).
    Conclusion: Severe COVID-19 pneumonia with hyperferritinemic inflammation is related to macrophage activation syndrome-like sepsis. An interdisciplinary intensive care teleconference as a quality tool for ICUs is proposed to detect patients with rare sepsis-like syndromes.
    MeSH term(s) Aged ; COVID-19 ; Critical Care ; Humans ; Inflammation ; Retrospective Studies ; SARS-CoV-2
    Keywords covid19
    Language German
    Publishing date 2020-10-28
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 2636018-4
    ISSN 2193-6226 ; 1435-1420 ; 0723-5003 ; 2193-6218 ; 0175-3851
    ISSN (online) 2193-6226 ; 1435-1420
    ISSN 0723-5003 ; 2193-6218 ; 0175-3851
    DOI 10.1007/s00063-020-00750-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.120: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.

    La Rosée, F / Bremer, H C / Gehrke, I / Kehr, A / Hochhaus, A / Birndt, S / Fellhauer, M / Henkes, M / Kumle, B / Russo, S G / La Rosée, P

    Leukemia

    2020  Volume 34, Issue 7, Page(s) 1805–1815

    Abstract: A subgroup of patients with severe COVID-19 suffers from progression to acute respiratory distress syndrome and multiorgan failure. These patients present with progressive hyperinflammation governed by proinflammatory cytokines. An interdisciplinary ... ...

    Abstract A subgroup of patients with severe COVID-19 suffers from progression to acute respiratory distress syndrome and multiorgan failure. These patients present with progressive hyperinflammation governed by proinflammatory cytokines. An interdisciplinary COVID-19 work flow was established to detect patients with imminent or full blown hyperinflammation. Using a newly developed COVID-19 Inflammation Score (CIS), patients were prospectively stratified for targeted inhibition of cytokine signalling by the Janus Kinase 1/2 inhibitor ruxolitinib (Rux). Patients were treated with efficacy/toxicity guided step up dosing up to 14 days. Retrospective analysis of CIS reduction and clinical outcome was performed. Out of 105 patients treated between March 30th and April 15th
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Anti-Inflammatory Agents/therapeutic use ; Betacoronavirus/drug effects ; Betacoronavirus/immunology ; Betacoronavirus/pathogenicity ; COVID-19 ; Clinical Trials as Topic ; Coronavirus Infections/drug therapy ; Coronavirus Infections/enzymology ; Coronavirus Infections/immunology ; Coronavirus Infections/virology ; Cytokine Release Syndrome/drug therapy ; Cytokine Release Syndrome/enzymology ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/virology ; Cytokines/antagonists & inhibitors ; Cytokines/genetics ; Cytokines/immunology ; Drug Administration Schedule ; Female ; Gene Expression Regulation ; Humans ; Immunity, Innate/drug effects ; Inflammation ; Janus Kinase 1/antagonists & inhibitors ; Janus Kinase 1/genetics ; Janus Kinase 1/immunology ; Janus Kinase 2/antagonists & inhibitors ; Janus Kinase 2/genetics ; Janus Kinase 2/immunology ; Male ; Middle Aged ; Nitriles ; Pandemics ; Patient Safety ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/enzymology ; Pneumonia, Viral/immunology ; Pneumonia, Viral/virology ; Protein Kinase Inhibitors/therapeutic use ; Pyrazoles/therapeutic use ; Pyrimidines ; Retrospective Studies ; SARS-CoV-2 ; Severe Acute Respiratory Syndrome/drug therapy ; Severe Acute Respiratory Syndrome/enzymology ; Severe Acute Respiratory Syndrome/immunology ; Severe Acute Respiratory Syndrome/virology ; T-Lymphocytes/drug effects ; T-Lymphocytes/immunology ; T-Lymphocytes/virology ; Treatment Outcome
    Chemical Substances Anti-Inflammatory Agents ; Cytokines ; Nitriles ; Protein Kinase Inhibitors ; Pyrazoles ; Pyrimidines ; ruxolitinib (82S8X8XX8H) ; JAK1 protein, human (EC 2.7.10.2) ; JAK2 protein, human (EC 2.7.10.2) ; Janus Kinase 1 (EC 2.7.10.2) ; Janus Kinase 2 (EC 2.7.10.2)
    Keywords covid19
    Language English
    Publishing date 2020-06-09
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 807030-1
    ISSN 1476-5551 ; 0887-6924
    ISSN (online) 1476-5551
    ISSN 0887-6924
    DOI 10.1038/s41375-020-0891-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2295: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies

    La Rosée, Felicitas / La Rosée, Paul

    Acta Haematologica

    2020  , Page(s) 1–3

    Keywords Hematology ; General Medicine ; covid19
    Language English
    Publisher S. Karger AG
    Publishing country ch
    Document type Article ; Online
    ZDB-ID 80008-9
    ISSN 1421-9662 ; 0001-5792
    ISSN (online) 1421-9662
    ISSN 0001-5792
    DOI 10.1159/000510770
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.145: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top